发明名称 Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
摘要 <p>Compositions and methods of treating various disorders by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents including retinoids, hydroxyurea, and flavonoids. Intravesicle methods of treatment of cancers phenylacetate. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention. A product as a combined preparation of phenylacetate and a retinoid, hydroxyurea, or flavonid (or other mevalonate pathway inhibitor) for simultaneous, separate, or sequential use in treating a neoplastic condition in a subject. Methods of modulating lipid metabolism and/or reducing serum triglycerides in a subject using phenylacetate.</p>
申请公布号 EP1523982(B1) 申请公布日期 2008.03.12
申请号 EP20040030912 申请日期 1994.10.12
申请人 THE GOVERNMENT OF THE UNITED STATES OF AMERICA ASREPRESENTED BY THE SECRETARY OF THE DEPARTMENT OFHEALTH AND HUMAN SERVICES 发明人 DVORIT, SAMID PH.D
分类号 A61K31/19;A61K31/353;A61K;A61K31/035;A61K31/07;A61K31/12;A61K31/17;A61K31/192;A61K31/20;A61K31/22;A61K31/35;A61K31/365;A61K31/70;A61K31/7072;A61K31/7076;A61K38/21;A61K38/22;A61K45/00;A61K45/06;A61P1/04;A61P3/00;A61P3/06;A61P3/08;A61P3/10;A61P7/00;A61P9/00;A61P13/02;A61P13/08;A61P13/10;A61P13/12;A61P15/00;A61P17/00;A61P17/02;A61P19/02;A61P25/00;A61P27/02;A61P29/00;A61P31/04;A61P31/12;A61P31/18;A61P35/00;A61P37/02;A61P37/04;A61P37/06;A61P43/00 主分类号 A61K31/19
代理机构 代理人
主权项
地址